As the surgical robotics community prepares for this year's Society of Robotic Surgery Annual Meeting, much of the discussion will understandably focus on technological innovation.
Artificial intelligence, digital surgery, advanced imaging, surgical analytics and the next generation of robotic platforms continue to attract significant investment and attention across our world.
What receives less attention is what happens after a company receives regulatory approval and begins the process of building a commercial organisation.
Having spent years supporting companies operating across surgical robotics, image-guided therapies and digital surgery technologies, it is often surprising how often commercial strategy becomes as much as, or a greater, challenge than the technology development itself.
The United States remains the largest opportunity for emerging robotic and surgical technology, but it is the most expensive by some way.
Launch Strategy, Geography & Focus
One of the most common assumptions is that market penetration can be accelerated by increasing the size (noise) of the commercial launch team. In reality, some of the most successful launches have been built through a selective approach.
Many organisations enter the market believing they need national coverage from day one. So, large sales teams are hired, territories are created across multiple regions, and significant capital and time is invested into commercial infrastructure. And this happens before there is a clear understanding of where physician advocacy, referral patterns and early clinical adoption are most likely.
Commercial costs (salaries, MBO's, guarantees etc) increase rapidly while utilisation remains concentrated within a relatively small number of health systems and physician champions.
Of course, a lot of this depends on the level of investment capital a company has but on the flip side, some companies take an overly conservative approach; where they achieve early traction in a handful of centers but fail to invest quickly enough in market development, physician education and commercial support. Competitors gain visibility, KOL's become aligned elsewhere and that early momentum isn't capitalized on.
The companies that appear to scale most effectively often identify a middle ground between the two.
Rather than focusing on broad geographic coverage, they focus resources on regions where there is already evidence of clinical interest (ideally via efficient therapy development/clinical marketing alongside submission) established; physician relationships, favorable patient groups and healthcare systems capable of supporting program development.
In robotic surgery, as we know, the initial sale is rarely the most important milestone but instead long-term adoption and utilization.
A robotic platform generating consistent procedural volume within a health system creates a far stronger foundation for expansion than multiple low-utilisation placements spread across a wide geography, because that clinical data & evidence becomes the engine room/sponsor for further capital sales in other major centers.
Hiring for Surgical Robotics Launch
The strongest early commercial hires are not always those with the largest capital sales backgrounds; we've seen several companies make mistakes with early launch hiring.
Rather than simply hiring supposed 'proven capital sales pro's', increasingly, successful firms are looking for individuals who understand the clinical pathway surrounding their approved procedure/indication because they can truly engage surgeons as peers, better understand hospital economics, reimbursement, and can support program development over an extended period of time.
For emerging technologies, the conversation inside a hospital extends well beyond procurement. Clinical leadership, service line directors, finance stakeholders, operating room management and physician champions likely will have their part to play in influencing adoption. How well the launch team understand how those groups interact can be as important as understanding the technology itself.
Ai Surgical Intelligence
Artificial intelligence is creating a similar dynamic in the Operating Room.
Many of the AI-enabled tools now entering operating rooms are not replacing surgeons but instead are helping improve workflow, procedural planning, imaging interpretation and decision support. Adoption actually depends on technical performance but also on how well those technologies integrate into existing clinical practice.
Hospitals continue to evaluate these investments through a combination of clinical outcomes, operational efficiency and economics. As a result, companies are best to build commercial teams with professionals that combine software expertise (O.R integration/capability) AND clinical knowledge/healthcare system experience rather than relying exclusively on traditional device sales or capital models.
Summary
As investment continues across robotics, AI and digital surgery, there is no shortage of innovation entering or intending to enter the market. The more interesting hurdle is how organisations translate that innovation into sustainable adoption.
In our view, the firms that establish the strongest positions over the next five years may not necessarily or always be those with the most advanced technology.
They are likely to be the firms that make disciplined commercial decisions on exactly where they launch, how they build clinical advocacy early and exactly what type of commercial talent/experience fits their specific model.
Finding that 'sweet spot' remains one of the most difficult hurdles of launching AND successfully scaling a surgical technology business in the United States.
.png)
